CureVac's coronavirus vaccine candidate has an efficacy of 48 per cent against Covid-19 illness across all age groups according to final study data, the company said late Wednesday. The German vaccine developer recently announced that its first-generation Covid-19 jab candidate had an efficacy of about 47 per cent according to a preliminary evaluation, dpa international reported. The announcement had caused a significant drop in firm's stock price and disappointment among ...